^
    Evidence Level:
    Sensitive: A1 - Approval

    [KRAS G12C-Non Small Cell Lung Cancer-adagrasib]

    Source:
    FDA
    Test:

    therascreen® KRAS RGQ PCR Kit, Resolution ctDx FIRST Assay

    Published date:
    12/12/2022
    Excerpt:
    KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.